Effect of an internet-based, personalized nutrition randomized trial on dietary changes associated with the Mediterranean diet: the Food4Me Study

BACKGROUND: Little is known about the efficacy of personalized nutrition (PN) interventions for improving consumption of a Mediterranean diet (MedDiet).

OBJECTIVE: The objective was to evaluate the effect of a PN intervention on dietary changes associated with the MedDiet.

DESIGN: Participants (n = 1607) were recruited into a 6-mo, Internet-based, PN randomized controlled trial (Food4Me) designed to evaluate the effect of PN on dietary change. Participants were randomly assigned to receive conventional dietary advice [control; level 0 (L0)] or PN advice on the basis of current diet [level 1 (L1)], diet and phenotype [level 2 (L2)], or diet, phenotype, and genotype [level 3 (L3)]. Dietary intakes from food-frequency questionnaires at baseline and at 6 mo were converted to a MedDiet score. Linear regression compared participant characteristics between high (>5) and low (≤5) MedDiet scores. Differences in MedDiet scores between treatment arms at month 6 were evaluated by using contrast analyses.

RESULTS: At baseline, high MedDiet scorers had a 0.5 lower body mass index (in kg/m(2); P = 0.007) and a 0.03 higher physical activity level (P = 0.003) than did low scorers. MedDiet scores at month 6 were greater in individuals randomly assigned to receive PN (L1, L2, and L3) than in controls (PN compared with controls: 5.20 ± 0.05 and 5.48 ± 0.07, respectively; P = 0.002). There was no significant difference in MedDiet scores at month 6 between PN advice on the basis of L1 compared with L2 and L3. However, differences in MedDiet scores at month 6 were greater in L3 than in L2 (L3 compared with L2: 5.63 ± 0.10 and 5.38 ± 0.10, respectively; P = 0.029).

CONCLUSIONS: Higher MedDiet scores at baseline were associated with healthier lifestyles and lower adiposity. After the intervention, MedDiet scores were greater in individuals randomly assigned to receive PN than in controls, with the addition of DNA-based dietary advice resulting in the largest differences in MedDiet scores. Although differences were significant, their clinical relevance is modest.

Personalized search over encrypted data with efficient and secure updates in mobile clouds

Mobile cloud computing has been involved as a key enabling technology to overcome the physical limitations of mobile devices towards scalable and flexible mobile services. In the mobile cloud environment, searchable encryption, which enables directly search over encrypted data, is a key technique to maintain both the privacy and usability of outsourced data in cloud. On addressing the issue, many research efforts resolve to using the searchable symmetric encryption (SSE) and searchable public-key encryption (SPE). In this paper, we improve the existing works by developing a more practical searchable encryption technique, which can support dynamic updating operations in the mobile cloud applications. Specifically, we make our efforts on taking the advantages of both SSE and SPE techniques, and propose PSU, a Personalized Search scheme over encrypted data with efficient and secure Updates in mobile cloud. By giving thorough security analysis, we demonstrate that PSU can achieve a high security level. Using extensive experiments in a realworld mobile environment, we show that PUS is more efficient compared with the existing proposals.

Chasing the personalized medicine dream through biomarker validation in colorectal cancer.

Colorectal cancer (CRC) is a major health burden worldwide. The optimal approach to the diagnosis, management, and treatment of CRC involves multidisciplinary and integrated management practices. The field is rapidly changing because of recent advancements in delineating the molecular basis of tumorigenesis, introduction of targeted therapy, varied patient response to mainstay chemotherapeutics, biological drugs, and the effective combination regimes being used for treatment. Recent meta-analysis studies, which tend to establish few clinically useful predictor biomarkers, identify inconsistent results and limitations of the trials. Therefore, molecular pathological epidemiology discipline initiatives are promising. Here, we provide an overview of the potential of biomarker validation for personalized medicine by focusing largely on metastatic (m)CRC. We also highlight new candidate predictive and prognostic biomarkers.